Rhythm Pharmaceuticals (RYTM) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Strategic focus and differentiation

• Emphasizes rare obesity as a distinct, multi-disease area, separate from general obesity, with a focus on hormonal replacement therapy targeting the MC4 pathway.

• Setmelanotide is positioned as a precision medicine for rare genetic and injury-driven obesity, unlike GLP-1s which target general obesity.

• Bardet-Biedl syndrome (BBS) and hypothalamic obesity (HO) are key indications, with BBS showing steady, durable growth and HO offering a new, more concentrated opportunity.

Clinical and commercial progress

• BBS launch since 2022 has shown stable, slow, and durable sales growth, typical for rare diseases.

• HO data, including recent adult results from France, demonstrated consistent and significant weight loss, with all patients responding, supporting expansion into this indication.

• Early access programs in Europe have confirmed efficacy in broader patient populations, including adults with long-standing disease.

Pipeline and future development

• Daybreak phase II data identified additional genetic targets for setmelanotide, with ongoing work to refine patient selection and expand indications.

• Next-generation assets include a daily oral and a weekly injectable, both aiming for improved specificity, convenience, and patent protection through 2040+.

• Plans to transition new drugs into all current indications and future opportunities, leveraging improved formulations.